Sihuan Pharmaceutical Holdings Group Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Sihuan Pharmaceutical Holdings Group de 117.7% y 25.5% por año respectivamente. Se prevé que el BPA crezca en un 123% al año. Se espera que la rentabilidad financiera sea de 6.7% en 3 años.

Información clave

117.7%

Tasa de crecimiento de los beneficios

123.0%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	12.4%
Tasa de crecimiento de los ingresos	25.5%
Rentabilidad financiera futura	6.7%
Cobertura de analistas	Low
Última actualización	16 Nov 2023

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Dec 05

Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?

Oct 31

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Aug 19

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Apr 21

Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?

Nov 03

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Oct 11

Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?

Jun 21

Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Mar 09

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Nov 28

Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly

Sep 26

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now

Jun 22

How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?

May 11

Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit

Mar 30

How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?

Mar 07

Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?

Feb 07

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Jan 11

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Dec 21

Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters

Dec 07

Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) A Risky Dividend Stock?

Jul 22

Previsiones de crecimiento de beneficios e ingresos

SEHK:460 - Estimaciones futuras de los analistas y datos financieros pasados (CNY Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	3,186	337	N/A	698	1
12/31/2024	2,733	107	N/A	328	1
12/31/2023	1,861	-54	-96	199	N/A
6/30/2023	1,773	-2,041	-697	-300	N/A
3/31/2023	1,977	-1,996	-620	-127	N/A
12/31/2022	2,181	-1,951	-543	46	N/A
6/30/2022	2,595	-144	-306	425	N/A
3/31/2022	2,817	141	-183	545	N/A
12/31/2021	3,038	427	-60	665	N/A
9/30/2021	3,304	681	63	740	N/A
6/30/2021	3,317	945	187	815	N/A
3/31/2021	2,891	727	-83	521	N/A
12/31/2020	2,464	508	-353	227	N/A
9/30/2020	2,370	-14	-429	214	N/A
6/30/2020	2,275	-537	-504	200	N/A
3/31/2020	2,577	-1,623	162	809	N/A
12/31/2019	2,878	-2,709	828	1,418	N/A
9/30/2019	3,088	-1,927	1,238	1,726	N/A
6/30/2019	3,297	-1,144	1,647	2,033	N/A
3/31/2019	3,107	238	1,525	1,913	N/A
12/31/2018	2,917	1,620	1,403	1,793	N/A
9/30/2018	2,751	1,496	1,481	1,906	N/A
6/30/2018	2,584	1,372	1,559	2,019	N/A
3/31/2018	2,665	1,411	1,495	1,968	N/A
12/31/2017	2,746	1,449	1,431	1,918	N/A
9/30/2017	2,992	1,632	N/A	1,889	N/A
6/30/2017	3,238	1,815	N/A	1,860	N/A
3/31/2017	3,212	1,761	N/A	1,939	N/A
12/31/2016	3,186	1,708	N/A	2,018	N/A
9/30/2016	2,984	1,528	N/A	2,037	N/A
6/30/2016	2,781	1,347	N/A	2,056	N/A
3/31/2016	2,974	1,705	N/A	1,812	N/A
12/31/2015	3,167	2,062	N/A	1,569	N/A
9/30/2015	3,321	2,181	N/A	1,691	N/A
6/30/2015	3,474	2,299	N/A	1,813	N/A
3/31/2015	3,279	1,985	N/A	1,787	N/A
12/31/2014	3,084	1,671	N/A	1,761	N/A
9/30/2014	2,365	1,581	N/A	1,650	N/A
6/30/2014	1,645	1,491	N/A	1,538	N/A
3/31/2014	2,116	1,388	N/A	1,556	N/A
12/31/2013	2,586	1,285	N/A	1,574	N/A
9/30/2013	4,355	1,182	N/A	1,408	N/A
6/30/2013	3,978	1,060	N/A	1,306	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que 460 sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (2%).

Beneficios vs. Mercado: Se prevé que 460 sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que 460 sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (25.5% al año) de 460 crezcan más rápidamente que los del mercado Hong Kong (7.7% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (25.5% al año) de 460 crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de 460 sea baja dentro de 3 años (6.7%).

Sihuan Pharmaceutical Holdings Group Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Consensus forecasts updated

Recent updates

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Upcoming dividend of HK$0.037 per share

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?

Upcoming dividend of HK$0.13 per share

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Investor sentiment improved over the past week

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Investor sentiment deteriorated over the past week

Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly

First half 2021 earnings released: EPS CN¥0.065 (vs CN¥0.018 in 1H 2020)

Non-Executive Director Jin-ha Kim has left the company

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Investor sentiment deteriorated over the past week

Upcoming dividend of HK$0.016 per share

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now

Sihuan Pharmaceutical Holdings Group Ltd. Announces Obtains Drug Registration Approval in Relation to Caspofungin Acetate for Injection

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Final Cash Dividend for the Year Ended December 31, 2020, Payable on or Around July 15, 2021

Investor sentiment improved over the past week

How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?

Investor sentiment improved over the past week

Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit

Sihuan Pharmaceutical Holdings Group Ltd. Recommends Two Special Cash Dividends

Full year 2020 earnings released: EPS CN¥0.054 (vs CN¥0.29 loss in FY 2019)

Sihuan Pharmaceutical Holdings Group Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?

New 90-day high: HK$2.75

Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?

Sihuan Pharmaceutical Holdings Group Ltd. Announces Selection of its Pantoprazole Sodium Injection (Panzuoer® 40mg per unit) and Ibuprofen Injection (Falanfen® 4ml: 0.4g, Tenaan® 8ml: 0.8g) in the Fourth Batch of National Drug Centralized Procurement

Sihuan Pharmaceutical Holdings Group Ltd. Announces Cinepazide Maleate Injection Obtain Approval from the National Medical Products Administration

New 90-day high: HK$1.32